IVI Hosts 17th International Vaccinology Course in Seoul on September 4-8
- Aeras Chief Medical Officer Dr. Ann Ginsberg delivers closing plenary speech on TB vaccine development; Korea University Prof. Woo-joo Kim to address Vaccine Preparedness and Response to Emerging Infectious Diseases
- 112 participants from 19 countries including trainees participate in this year’s event hosted jointly by IVI, KOHI
- 35 experts from international agencies, research institutions, universities, industry and non-profit organizations, including IVI, WHO and U.S. NIH serve as faculty members
September 4, 2017, SEOUL — The International Vaccine Institute (IVI), an international organization devoted to the development and introduction of new vaccines for global public health, convened the 17th International Vaccinology Course (IVC) at the IVI headquarters in Seoul from September 4 to 8. This year’s course was co-hosted by the Korea Human Resources Development Institute for Health and Welfare (KOHI), a state-run agency under the Ministry of Health and Welfare, for the first time.
|Dr. Jerome Kim (podium), Director General of the International Vaccine Institute (IVI), delivers welcome remarks to participants at the opening of the 17th International Vaccinology Course at the IVI headquarters on September 4. This year's course, which is co-hosted by IVI and the Korea Human Resources Development Institute for Health and Welfare (KOHI) for the first time, will continue through September 8 to help strengthen developing country capacity in vaccines and vaccination.|
The annual course aims to build capacity of vaccine professionals, especially from developing countries, in vaccinology from vaccine discovery to development to introduction in order to help increase developing country capacity in vaccines and vaccination. The course has trained over 1,000 professionals for 16 years. This year’s course brings together 147 participants from 19 countries, including trainees and faculty from Korea, the U.S., the U.K., France, India, and the Philippines. The trainees include 10 students from developing countries such as Kenya and Vietnam who were awarded fellowships, which were made possible due to support from donors and sponsors.
Lectures by leading experts in vaccinology and interactive case studies cover topics that include immunology, epidemiology, vaccine design and clinical development, vaccine process development and manufacturing, regulatory and data management, licensure to introduction, and introduction to use including vaccine communications, and vaccine effectiveness and safety. More than 30 experts from international agencies, including IVI and the World Health Organization; research organizations, including the U.S. National Institutes of Health; industry; universities; and non-profit organizations serve as faculty members. Notably, Dr. Ann Ginsberg, Chief Medical Officer at Aeras, will give the plenary lecture to address development of tuberculosis (TB) vaccine. Aeras based on the U.S. is a not-for-profit biotechnology organization developing improved TB vaccines for the world.
The course also features a series of topical lectures including, Development of a DNA Vaccine against Zika Virus by Dr. Sung-youl Ko, the National Institute of Allergy and Infectious Diseases, US NIH; Maternal Immunization by Dr. Flor Munoz from Baylor College of Medicine in the U.S.; and Post-registration Safety Monitoring by Dr. Patrick Zuber from WHO. In addition, Prof. Woo-joo Kim of Korea University Hospital will give a talk on Vaccine Preparedness and Response to Emerging Infectious Diseases, while Dr. Youngmee Jee, Director General of the Center for Pathology and Immunology from the Korea Centers for Disease Control & Prevention and a member of WHO Strategic Advisory Group of Experts (SAGE) on Immunization, will deliver closing remarks.
This year’s course is supported by the Korea Human Resources Development Institute for Health and Welfare (KOHI), GlaxoSmithKline (GSK), Green Cross, Sky72 Golf Club, Community Chest of Korea Incheon, Chong Kun Dang Kochon Foundation, and RAPHAS.
About International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
Tae Kyung Byun
Public Awareness/Advocacy Officer, IVI
Phone: +82-2-872-2801 (Ext. 159)